Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.685 |
---|---|
High | 0.685 |
Low | 0.685 |
Bid | 0.535 |
Offer | 0.635 |
Previous close | 0.685 |
Average volume | 5.56 |
---|---|
Shares outstanding | 6.67m |
Free float | 6.52m |
P/E (TTM) | -- |
Market cap | 4.30m USD |
EPS (TTM) | -3.36 USD |
Data delayed at least 15 minutes, as of Oct 09 2024 07:04 BST.
More ▼
Announcements
- Predictive Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Predictive Oncology Study Demonstrates Long-Term Stability and Viability of Proprietary Biobank of Primary Tumor Specimens for Pharmaceutical Drug Discovery
- Predictive Oncology Reports Second Quarter 2024 Financial Results and Provides Business Update
- Predictive Oncology Expands the Application of its Live-Cell Tumor Platform to De-Risk Drug Discovery and Accelerate Pipeline Development
- Predictive Oncology to Report Second Quarter 2024 Financial Results on Wednesday, August 14, 2024
- Predictive Oncology Announces Exercise of Warrants for $1.26 Million Gross Proceeds
- Predictive Oncology Enters Biomarker Discovery Market After Successful Retrospective Ovarian Cancer Study Yields Compelling Results
- Predictive Oncology Develops Novel Stem Cell Expression System for the Production of Functional and Stable G-Protein Coupled Receptors (GPCRs)
- Predictive Oncology Launches Novel 3D Cell Technology to Accelerate Cancer Therapeutic Drug Discovery
- Predictive Oncology Announces CEO Raymond Vennare to Present at the BIO International Convention 2024
More ▼